Dossier assessment

Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-154
Last updated

Report documents

  1. Extract of dossier assessment

    Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 735 kB, EN, not accessible
  2. Dossier assessment

    Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible

Dossier assessment

Indication:

Adult patients with unresectable or metastatic triple-negative breast cancer who have had two or more prior systemic therapies including at least one of them for advanced disease

Result of dossier assessment:

Hint of major added benefit

Press releases

Triple-negative breast cancer: survival advantage with sacituzumab govitecan

Median survival time of affected patients was 12 months compared to seven in the control group. Overall, the Institute sees a hint of major added benefit versus the comparator therapy.

Additional information

Federal Joint Committee (G-BA)

2022-05-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-154
Commission
Commission awarded on 01.12.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Addendum

    Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154

    Project no.
    A22-41
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-86
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form